The 7 major acromegaly markets are expected to exhibit a CAGR of 8.1% during 2023-2034.
The acromegaly market has been comprehensively analyzed in this report titled "Acromegaly Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acromegaly refers to a rare, chronic disorder caused by the excessive production of growth hormone (GH), usually by a benign tumor of the pituitary gland known as an adenoma. This condition typically presents in middle-aged adults, leading to the abnormal growth of bones and tissues, notably in the hands, feet, and face. The symptoms of acromegaly often develop gradually and can include enlarged hands and feet, facial changes, such as a protruding jaw or enlarged nose, thickened skin, joint pain, and increased spacing between teeth. Individuals suffering from the ailment may also experience complications like cardiovascular issues, diabetes, and sleep apnea due to the hormonal imbalances caused by excess GH. The diagnosis typically involves blood tests to measure GH and insulin-like growth factor-1 (IGF-1) levels, which are elevated in acromegaly. The healthcare provider may also recommend several imaging studies, such as MRI or CT scans, to locate and assess the pituitary tumor in patients.
The increasing prevalence of changes in certain genes within the pituitary cells that can lead to the development of adenomas is primarily driving the acromegaly market. In addition to this, the inflating utilization of efficacious medications like somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists to regulate hormone levels and manage symptoms effectively is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical interventions, such as transsphenoidal surgery and radiation therapy, which aim to remove or shrink the pituitary tumor responsible for the excess GH production in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of physical and occupational therapies, since they assist in improving mobility, enhancing muscle strength, and addressing the challenges associated with the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine, that prioritizes patient genetic makeup to optimize therapeutic interventions and minimize adverse effects, is also augmenting the market growth. Furthermore, the escalating application of novel treatment modalities, such as targeted therapies that focus on specific molecular and cellular pathways, is expected to drive the acromegaly market during the forecast period.
This report provides an exhaustive analysis of the acromegaly market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acromegaly and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acromegaly market in any manner.
Recent Developments:
In March 2024, Crinetics Pharmaceuticals, Inc. reported positive topline findings from PATHFNDR-2, the second of two Phase 3 studies assessing the efficacy and safety of paltusotine, an oral, once-daily experimental therapy for acromegaly.
In June 2023, Camurus reported positive topline findings from ACROINNOVA 1, a 24-week Phase 3 randomized, double-masked, placebo-controlled trial that assessed the efficacy and safety of the company's octreotide subcutaneous (SC) depot (CAM2029) in adult individuals with acromegaly. The solution is designed for convenient, once-monthly administration with a ready-to-use syringe or injectable pen to assist patient administration.
In March 2023, Chiesi Global Rare Diseases disclosed the launch of Rethink Acromegaly, a disease education initiative. The goal is to provide audiences with the most up-to-date information and resources to help persons living with acromegaly, their caregivers, and healthcare providers.
Key Highlights:
The overall prevalence of acromegaly ranges between 2.8 and 13.7 occurrences per 100,000 individuals, with yearly incidence rates ranging from 0.2 to 1.1 cases/100,000 persons.
The typical age at diagnosis is in the fifth decade of life, with a 4.5-year median diagnostic delay.
According to the study, roughly 3,000 new cases of acromegaly are diagnosed each year, with an estimated 25,000 acromegaly patients in the United States.
It is estimated that the current incidence of acromegaly in the United States could be up to four times greater, with a prevalence of up to 50% higher than previously recorded in European studies.
Acromegaly is related to an increased risk of mortality from vascular and pulmonary disease, according to research presented at the annual conference of the Endocrine Society (ENDO 2020).
Drugs:
Sandostatin LAR is a long-acting octreotide formulation used to treat individuals with acromegaly. Sandostatin LAR is approved at doses of 10, 20, and 30 mg (and up to 40 mg for patients with acromegaly in certain countries such as the US and Japan), allowing for once-monthly administration, maintaining the efficacy of Sandostatin immediate-release while significantly reducing the number of injections administered.
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist for acromegaly. It was designed by the Crinetics discovery team to provide an effective and easy once-daily solution for those suffering from acromegaly. In a recently completed PATHFNDR-1 Phase 3 study, paltusotine maintained IGF-1 levels in acromegaly patients who converted from monthly injectable medicines to paltusotine.
CAM2029 (octreotide SC depot) is a ready-to-use octreotide subcutaneous depot currently under development for the treatment of acromegaly. The medicine is intended to be administered once a month using an injectable pen, making it simple for patients to administer themselves. The efficacy and safety of octreotide SC depot in acromegaly are now being evaluated in the ACROINNOVA program.
The acromegaly market has been comprehensively analyzed in this report titled "Acromegaly Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acromegaly refers to a rare, chronic disorder caused by the excessive production of growth hormone (GH), usually by a benign tumor of the pituitary gland known as an adenoma. This condition typically presents in middle-aged adults, leading to the abnormal growth of bones and tissues, notably in the hands, feet, and face. The symptoms of acromegaly often develop gradually and can include enlarged hands and feet, facial changes, such as a protruding jaw or enlarged nose, thickened skin, joint pain, and increased spacing between teeth. Individuals suffering from the ailment may also experience complications like cardiovascular issues, diabetes, and sleep apnea due to the hormonal imbalances caused by excess GH. The diagnosis typically involves blood tests to measure GH and insulin-like growth factor-1 (IGF-1) levels, which are elevated in acromegaly. The healthcare provider may also recommend several imaging studies, such as MRI or CT scans, to locate and assess the pituitary tumor in patients.
The increasing prevalence of changes in certain genes within the pituitary cells that can lead to the development of adenomas is primarily driving the acromegaly market. In addition to this, the inflating utilization of efficacious medications like somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists to regulate hormone levels and manage symptoms effectively is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical interventions, such as transsphenoidal surgery and radiation therapy, which aim to remove or shrink the pituitary tumor responsible for the excess GH production in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of physical and occupational therapies, since they assist in improving mobility, enhancing muscle strength, and addressing the challenges associated with the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine, that prioritizes patient genetic makeup to optimize therapeutic interventions and minimize adverse effects, is also augmenting the market growth. Furthermore, the escalating application of novel treatment modalities, such as targeted therapies that focus on specific molecular and cellular pathways, is expected to drive the acromegaly market during the forecast period.
This report provides an exhaustive analysis of the acromegaly market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acromegaly and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acromegaly market in any manner.
Recent Developments:
In March 2024, Crinetics Pharmaceuticals, Inc. reported positive topline findings from PATHFNDR-2, the second of two Phase 3 studies assessing the efficacy and safety of paltusotine, an oral, once-daily experimental therapy for acromegaly.
In June 2023, Camurus reported positive topline findings from ACROINNOVA 1, a 24-week Phase 3 randomized, double-masked, placebo-controlled trial that assessed the efficacy and safety of the company's octreotide subcutaneous (SC) depot (CAM2029) in adult individuals with acromegaly. The solution is designed for convenient, once-monthly administration with a ready-to-use syringe or injectable pen to assist patient administration.
In March 2023, Chiesi Global Rare Diseases disclosed the launch of Rethink Acromegaly, a disease education initiative. The goal is to provide audiences with the most up-to-date information and resources to help persons living with acromegaly, their caregivers, and healthcare providers.
Key Highlights:
The overall prevalence of acromegaly ranges between 2.8 and 13.7 occurrences per 100,000 individuals, with yearly incidence rates ranging from 0.2 to 1.1 cases/100,000 persons.
The typical age at diagnosis is in the fifth decade of life, with a 4.5-year median diagnostic delay.
According to the study, roughly 3,000 new cases of acromegaly are diagnosed each year, with an estimated 25,000 acromegaly patients in the United States.
It is estimated that the current incidence of acromegaly in the United States could be up to four times greater, with a prevalence of up to 50% higher than previously recorded in European studies.
Acromegaly is related to an increased risk of mortality from vascular and pulmonary disease, according to research presented at the annual conference of the Endocrine Society (ENDO 2020).
Drugs:
Sandostatin LAR is a long-acting octreotide formulation used to treat individuals with acromegaly. Sandostatin LAR is approved at doses of 10, 20, and 30 mg (and up to 40 mg for patients with acromegaly in certain countries such as the US and Japan), allowing for once-monthly administration, maintaining the efficacy of Sandostatin immediate-release while significantly reducing the number of injections administered.
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist for acromegaly. It was designed by the Crinetics discovery team to provide an effective and easy once-daily solution for those suffering from acromegaly. In a recently completed PATHFNDR-1 Phase 3 study, paltusotine maintained IGF-1 levels in acromegaly patients who converted from monthly injectable medicines to paltusotine.
CAM2029 (octreotide SC depot) is a ready-to-use octreotide subcutaneous depot currently under development for the treatment of acromegaly. The medicine is intended to be administered once a month using an injectable pen, making it simple for patients to administer themselves. The efficacy and safety of octreotide SC depot in acromegaly are now being evaluated in the ACROINNOVA program.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the acromegaly market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the acromegaly market
Competitive Landscape:
This report also provides a detailed analysis of the current acromegaly marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the acromegaly market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the acromegaly market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the acromegaly market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of acromegaly across the seven major markets?
- What is the number of prevalent cases (2018-2034) of acromegaly by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of acromegaly by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with acromegaly across the seven major markets?
- What is the size of the acromegaly patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of acromegaly?
- What will be the growth rate of patients across the seven major markets?
Acromegaly: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for acromegaly drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acromegaly market?
- What are the key regulatory events related to the acromegaly market?
- What is the structure of clinical trial landscape by status related to the acromegaly market?
- What is the structure of clinical trial landscape by phase related to the acromegaly market?
- What is the structure of clinical trial landscape by route of administration related to the acromegaly market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Acromegaly - Unmet Needs10 Acromegaly - Key Endpoints of Treatment13. Acromegaly - Attribute Analysis of Key Marketed and Pipeline Drugs16 Acromegaly - Recent Events and Inputs From Key Opinion Leaders18 Acromegaly Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Acromegaly - Introduction
5 Acromegaly - Disease Overview
7 Acromegaly - Epidemiology and Patient Population
8 Acromegaly - Treatment Algorithm, Guidelines, and Medical Practices
11 Acromegaly - Marketed Products
12 Acromegaly - Pipeline Drugs
14. Acromegaly - Clinical Trial Landscape
15 Acromegaly - Market Scenario
17 Acromegaly Market - SWOT Analysis
Methodology
LOADING...
